Literature DB >> 18606413

Ethnic variation in levels of circulating IgG autoantibodies to oxidised low-density lipoprotein.

Michelle A Miller1, Pasquale Strazzullo, Sharada Karanam, Francesco P Cappuccio.   

Abstract

BACKGROUND: Oxidised low-density lipoprotein (Ox-LDL) plays a key role in atherosclerosis. Our aim was to determine whether serum autoantibodies against Ox-LDL (Ab Ox-LDL) differ by ethnic group. DESIGN AND METHODS: Soluble serum Ab Ox-LDL levels were measured in 250 white (113 females), 169 African origin (91 females) and 196 South Asian (92 females) individuals from the Wandsworth Heart and Stroke Study (WHSS) population. All were free from coronary heart disease (CHD), stroke, other cardiovascular disease, diabetes, drug therapy for hypertension or high lipids, hormone replacement therapy or oral contraceptive pill.
RESULTS: There were no sex differences in levels of Ab Ox-LDL, but levels were higher in non-smokers (430U/L [95% CI 471-596]) than in smokers (384U/L [316-468]) (p<0.009). Age- and sex-adjusted levels of Ab Ox-LDL were higher in people of African origin and South Asians compared to whites. This difference was maintained in South Asian women following adjustment for multiple risk factors (82% [21-175]; p=0.004). Ab Ox-LDL levels were negatively associated with serum triglycerides and positively associated with sVCAM-1.
CONCLUSIONS: Higher IgG Ab to Ox-LDL are associated with higher levels of sVCAM-1 and, are elevated in female South Asian individuals who have an increased risk of atherosclerosis compared to whites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606413     DOI: 10.1016/j.atherosclerosis.2008.05.053

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  1 in total

Review 1.  Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis.

Authors:  DeLisa Fairweather; Michelle A Petri; Michael J Coronado; Leslie T Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-03       Impact factor: 4.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.